经导管与外科主动脉瓣置换术倾向匹配比较
基于美国TVT注册与STS数据库链接医保索赔的倾向匹配队列,纳入9,464例中高危主动脉瓣狭窄患者,比较TAVR与SAVR。两组1年死亡、卒中和存活出院天数无差异,但TAVR出院回家比例更高。
要点
- 中高危患者TAVR与SAVR的1年死亡和卒中发生率相似
- TAVR组出院回家比例显著高于SAVR组
- 结果在多数亚组中一致,支持TAVR在真实世界中的应用
核心结论
- 在未经选择的中高危患者中,TAVR与SAVR的1年死亡、卒中和存活出院天数相似,但TAVR患者更可能出院回家。
研究设计与样本
- 使用TVT注册和STS国家数据库链接Medicare索赔数据,进行倾向匹配分析,纳入9,464例中高危(STS预测死亡风险≥3%)美国患者。
主要发现
- 倾向匹配队列中位年龄82岁,女性48%,中位STS预测死亡风险5.6%。
- 1年死亡率TAVR 17.3% vs SAVR 17.9%,HR 0.93(95%CI 0.83-1.04)。
- 1年卒中率TAVR 4.2% vs SAVR 3.3%,HR 1.18(95%CI 0.95-1.47)。
- 1年存活出院天数率比1.00(95%CI 0.98-1.02)。
- 出院回家比例TAVR 69.9% vs SAVR 41.2%,OR 3.19(95%CI 2.84-3.58)。
临床怎么用
- 对于中高危主动脉瓣狭窄患者,TAVR可作为SAVR的替代选择,尤其注重出院回家可能性的患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Randomized trials support the use of transcatheter aortic valve replacement (TAVR) for the treatment of aortic stenosis in high- and intermediate-risk patients, but the generalizability of those results in clinical practice has been challenged. OBJECTIVES: The aim of this study was to determine the safety and effectiveness of TAVR versus surgical aortic valve replacement (SAVR), particularly in intermediate- and high-risk patients, in a nationally representative real-world cohort. METHODS: Using data from the Transcatheter Valve Therapy Registry and Society of Thoracic Surgeons National Database linked to Medicare administrative claims for follow-up, 9,464 propensity-matched intermediate- and high-risk (Society of Thoracic Surgeons Predicted Risk of Mortality score ≥3%) U.S. patients who underwent commercial TAVR or SAVR were examined. Death, stroke, and days alive and out of the hospital to 1 year were compared, as well as discharge home, with subgroup analyses by surgical risk, demographics, and comorbidities. RESULTS: In a propensity-matched cohort (median age 82 years, 48% women, median Society of Thoracic Surgeons Predicted Risk of Mortality score 5.6%), TAVR and SAVR patients experienced no difference in 1-year rates of death (17.3% vs. 17.9%; hazard ratio: 0.93; 95% confidence interval [CI]: 0.83 to 1.04) and stroke (4.2% vs. 3.3%; hazard ratio: 1.18; 95% CI: 0.95 to 1.47), and no difference was observed in the proportion of days alive and out of the hospital to 1 year (rate ratio: 1.00; 95% CI: 0.98 to 1.02). However, TAVR patients were more likely to be discharged home after treatment (69.9% vs. 41.2%; odds ratio: 3.19; 95% CI: 2.84 to 3.58). Results were consistent across most subgroups, including among intermediate- and high-risk patients. CONCLUSIONS: Among unselected intermediate- and high-risk patients, TAVR and SAVR resulted in similar rates of death, stroke, and DAOH to 1 year, but TAVR patients were more likely to be discharged home.
引用
- Brennan JM, Thomas L, Cohen DJ, et al. Transcatheter Versus Surgical Aortic Valve Replacement: Propensity-Matched Comparison. J Am Coll Cardiol. 2017. PMID: 28728688. doi:10.1016/j.jacc.2017.05.060
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。